ArticleOncotarget2017
De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cancer risk in heart or lung transplant recipients: A comprehensive analysis of 21 prospective cohorts.Cancer medicine · 2020Pooled it
- Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies.Oncoimmunology · 2020Pooled it
- Spectrum of cancer risk in Asian American and Pacific Islander solid organ transplant recipients.Journal of the National Cancer Institute · 2025Article
- Frontiers and Controversies in De Novo Gastrointestinal Tumors After Organ Transplantation: Current Progress and Future Directions.Annals of surgical oncology · 2025Review
- Lung cancer after kidney transplantation: a 50-year experience at a single institution.Surgery today · 2024Article
- NTRK3 exhibits a pro-oncogenic function in upper tract urothelial carcinomas.The Kaohsiung journal of medical sciences · 2024Article
- Pancreatic cancer among solid organ transplant recipients in the United States.Journal of cancer research and clinical oncology · 2023Article
- Whole-exome sequencing identified mutational profiles of urothelial carcinoma post kidney transplantation.Journal of translational medicine · 2022Article
- The Spectrum of Malignant Neoplasms among Liver Transplant Recipients: Sociodemographic Factors, Mortality, and Hospital Burden.International journal of medical sciences · 2022Article
- Progression of the atypical fibroxanthoma to pleomorphic dermal sarcoma in a heart transplant patient.BMJ case reports · 2021Article
- High Incidence and Early Onset of Urinary Tract Cancers in Patients with BK Polyomavirus Associated Nephropathy.Viruses · 2021Observational
- Timing of mTORI usage and outcomes in kidney transplant recipients.International journal of medical sciences · 2021Observational
- Relative and absolute cancer risks among Nordic kidney transplant recipients-a population-based study.Transplant international : official journal of the European Society for Organ Transplantation · 2020Article
- De novo cancer incidence after kidney and liver transplantation: Results from a nationwide population based data.Scientific reports · 2019Article
- Advanced native-kidney carcinoma in a heart- and kidney-transplanted patient: a case report.CEN case reports · 2018Article
- Incidence ofSaudi journal of medicine & medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organ transplant recipients appear to have a higher risk of de novo malignancy. The aim of the study was designed to estimate cancer risk in heart, lung, kidney and liver transplant recipients. The cohort study used the Taiwan National Health Insurance Research Database (1996-2011) and followed the outcomes of organ recipients until 2012. De novo cancer and mortality rates after organ transplantation were evaluated using standardized incidence ratios, excess absolute risks of cancer, and standardized mortality ratios in recipients were compared with those in the general population. We identified 40, 231, 2, and 115 patients who developed cancer after heart, kidney, lung, and liver transplantation, which corresponded to a cancer incidence of 878.4, 1101.2, 728.9, and 1361.4 cases per 100,000 person-years, respectively. In heart, kidney, lung, and liver recipients, the overall standardized incidence ratios were 1.65 (1.21-2.24), 3.33 (2.93-3.79), 1.82 (0.45-7.27) and 3.37 (2.81-4.05) and the overall standardized mortality ratios were 5.45 (4.96-5.98), 1.47 (1.34-1.61), 8.92 (7.10-11.20), and 3.83 (3.48-4.20), respectively. These results reveal a three-fold increase in de novo cancer risk in organ transplant patients compared with the general population. This study illustrated the importance of de novo malignancy after organ transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.